sevelamer hydrochloride / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 34 Diseases   4 Trials   4 Trials   108 News 
  • ||||||||||  sevelamer carbonate / Generic mfg., sevelamer hydrochloride / Generic mfg.
    SEVELAMER-INDUCED COLITIS: A CONCISE REVIEW FOR CLINICIANS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_5094;    
    Sevelamer crystals can be identified in the fibropurulent necrotic debris of the ulcerated tissue, displaying a characteristic 'fish scale' pattern on histology. 6 Even though the etiopathogenesis of SIC remains unclear, temporality, dose-response relationship 9 , and biologic plausibility have been established further strengthening the causation hypothesis.
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    THE COURSE OF OSTEODYSTROPHY IN PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE RECEIVING PROGRAMMED HEMODIALYSIS (Focussed Oral Room 7) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1654;    
    The use of calcium carbonate, biphosphonate and vitamin D3 contributes to an increase in the mineral density of the femoral neck by 8.64% (p<0.05). The introduction of sevelamer hydrochloride into the therapy regimen increases the effectiveness of therapy and increases the mineral density of the bodies of the lumbar vertebrae by 5.96% (p< 0.05) and the femoral neck by 14.04% (p<0.05).
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    ASSESSMENT OF EXTRA-BONE CALCIFICATION IN PATIENTS UNDERGOING PROGRAMMED HEMODIALYSIS (Focussed Oral Room 10) -  May 4, 2023 - Abstract #ERAEDTA2023ERA_EDTA_1396;    
    The introduction of sevelamer hydrochloride into the therapy regimen is associated with the prevention of the progression of cardiac remodeling. Calcification of the aortic valve progresses, regardless of the therapy used.
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Effect of guanidinium content on the anion binding capacity of polyallylamine-based polymer networks (Hall F-H (Indiana Convention Center)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_9020;    
    The starting point was the phosphate-binding drug sevelamer hydrochloride, a polymer of allylamine used to treat hyperphosphatemia in chronic kidney disease...Lastly, a colorimetric enzyme-based assay is being used to study bile acid absorption by the polymers, but these studies are still in progress. Overall, these results will inform future design of polymer resins for treatment of medical conditions and environmental remediation.
  • ||||||||||  sevelamer carbonate / Generic mfg., sevelamer hydrochloride / Generic mfg.
    Gastrointestinal Tract Injuries Associated With Sevelamer: A Systematic Review (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_1760;    
    Diabetes was present in 27% of cases and at least one risk factor to have slow GIT motility was identified in 63.3% of patients. Both sevelamer carbonate and sevelamer hydrochloride were reported to be associated with GIT injury.
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Journal:  Enhancing the Phosphate Adsorption of a Polyallylamine Resin in Alkaline Environments by Lanthanum Oxalate Modification. (Pubmed Central) -  Jun 22, 2022   
    Sevelamer hydrochloride (SH), originally developed as an oral pharmaceutical for controlling blood phosphate levels, is a polyallylamine resin that could be used in water treatments...Both factors lead to the improved adsorption properties. The modification by lanthanum oxalate species might provide a new alternative for improving the phosphate adsorption properties of anion-exchange resins.
  • ||||||||||  Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
    Real-World Adherence and Persistence on Phosphate Binders Among Dialysis-Dependent Patients With Chronic Kidney Disease () -  Mar 6, 2022 - Abstract #NKFSCM2022NKF_SCM_706;    
    Further studies are needed to determine the reasons for these findings on use of PB and its variation across different binders within the class. These studies could identify opportunities for better control of phosphate levels among patients with CKD.
  • ||||||||||  Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
    Real-World All-Cause Healthcare Costs Among Dialysis-Dependent Patients With Chronic Kidney Disease on Phosphate Binders () -  Mar 6, 2022 - Abstract #NKFSCM2022NKF_SCM_705;    
    Further studies are needed to determine if healthcare utilization and outcomes, particularly for services in the CMS ESRD bundle, also vary. These studies could identify opportunities for better control of phosphate levels among patients with CKD.
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Journal:  Sevelamer Attenuates Bioprosthetic Heart Valve Calcification. (Pubmed Central) -  Oct 22, 2021   
    Sevelamer treatment significantly attenuated the calcification of BHVs and had anti-inflammation effects that were independent from serum calcium and phosphate regulation. Thus, sevelamer treatment might be helpful to improve the longevity of BHVs.
  • ||||||||||  Auryxia (ferric citrate) / Japan Tobacco, Akebia Therap, Fosrenol (lanthanum carbonate) / Takeda, Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Vifor, Kissei
    [VIRTUAL] Real-World Use of Phosphate Binder Agents Among Dialysis-Dependent Patients with CKD in Medicare Fee-for-Service () -  Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2171;    
    Binder use was reported in 60% of all outpatient dialysis months for patients in our study, suggesting that PBs may have been underutilized or required only intermittently. Further studies are needed to determine the reasons for gaps in PB use and to identify opportunities for control of phosphate levels among patients with DD ESRD.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Trial completion date, Trial primary completion date, Metastases:  Different Effects of Non-calcium Phosphate Binders on Serum Calcium (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=34, Completed, 
    Further studies are needed to determine the reasons for gaps in PB use and to identify opportunities for control of phosphate levels among patients with DD ESRD. Trial completion date: Jun 2015 --> Dec 2020 | Trial primary completion date: Jul 2013 --> Dec 2020
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Journal:  Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis. (Pubmed Central) -  Jan 28, 2021   
    In vitro permeability assays revealed that chenodeoxycholic acid (CDCA), which was elevated in the cecum of WD-fed mice, increased paracellular permeability, while the BA-binding resin sevelamer hydrochloride protected against CDCA-induced loss of barrier function...Sevelamer also reduced hepatic inflammation and fibrosis, and improved metabolic derangements associated with NASH. Collectively, these findings highlight a hitherto unappreciated role for BAs in WD-induced impairment of the intestinal epithelial barrier in NASH.
  • ||||||||||  Renagel (sevelamer) / Sanofi
    [VIRTUAL] A Case of Sevelamer-Induced Colon Perforation (On-Demand) -  Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_2800;    
    Recognition of characteristic sevelamer crystals (typically seen as bright pink linear accentuations with a rusty yellow background and irregularly spaced fish-scales) on pathology along with the supporting clinical history clinches the diagnosis. It is important for clinicians to be aware of this rare but a serious potential complication of bowel perforation associated with sevelamer.
  • ||||||||||  Fosrenol (lanthanum carbonate) / Takeda
    Clinical, Review, Journal:  Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease. (Pubmed Central) -  Sep 30, 2020   
    Moreover, the use of lanthanum carbonate has been associated with better nutritional status compared to other phosphate binders, lower risk for hypercalcemia than calcium-containing binders, and amelioration of mild metabolic acidosis contrary to sevelamer hydrochloride. Main adverse effects include nausea, alkaline gastric reflux, gastric deposition of lanthanum, gastrointestinal obstruction, subileus, ileus, perforation, fecal impaction, and reduction of gastrointestinal absorption of some drugs including statins, angiotensin-converting enzyme inhibitors and some antibiotics such as fluoroquinolones or tetracyclines.
  • ||||||||||  Renagel (sevelamer) / Sanofi, Kiklin (bixalomer) / Astellas, Fosrenol (lanthanum carbonate) / Takeda
    Journal:  Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals. (Pubmed Central) -  Mar 27, 2019   
    However, it should be emphasized that patients undergoing dialysis do not have a urinary excretion route and are administered many phosphate binder pills every day over a long period of time. In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores.
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Trial termination, Trial primary completion date:  NICOREN: Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients (clinicaltrials.gov) -  May 16, 2016   
    P3,  N=176, Terminated, 
    In the future, pharmaceutical companies may have to disclose standard amounts and/or analytical values regarding the type and quantity of metallic elements in the final formulation or pharmaceutical bulk derived from natural ores. Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jun 2013; Financial problem
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Trial completion:  SERENE: Sevelamer Hydrochloride in Peritoneal Dialysis Patients (clinicaltrials.gov) -  Sep 9, 2015   
    P=N/A,  N=60, Completed, 
    Recruiting --> Terminated | Trial primary completion date: Dec 2012 --> Jun 2013; Financial problem Active, not recruiting --> Completed
  • ||||||||||  Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Kissei
    Trial completion, Trial primary completion date:  A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia (clinicaltrials.gov) -  Nov 13, 2014   
    P3,  N=0, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Dec 2013
  • ||||||||||  Velphoro (sucroferric oxyhydroxide) / Fresenius Kabi, Kissei
    Enrollment closed:  A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia (clinicaltrials.gov) -  May 28, 2014   
    P3,  N=0, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2014 --> Dec 2013 Recruiting --> Active, not recruiting
  • ||||||||||  sevelamer hydrochloride / Generic mfg.
    Enrollment closed:  SERENE: Sevelamer Hydrochloride in Peritoneal Dialysis Patients (clinicaltrials.gov) -  Jun 18, 2013   
    P=N/A,  N=60, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting